Indian pharma industry estimated to grow 9 to 11 percent in FY22: ICRA

In FY22, the sample set is estimated to have witnessed growth of 13-15 per cent in the domestic market, 14-16 per cent in the emerging markets and 9-11 per cent in the European business, she added.

Macherla said growth under the US business is expected to remain muted given the pricing pressure.

In the domestic market, ICRA said a combination of steady normalisation in hospital footfalls and field force operations, given the relatively lower restrictions on account of Covid-19, continued traction in acute therapies and better pricing supported healthy revenue growth across companies.

Going forward, the ratings agency said sustenance of trend in doctor visits and elective surgeries given the news around the Omicron variant, and performance of new launches in addition to revenue growth momentum in the acute segment will remain key monitorables.

ICRA said the emerging markets were the star performers clocking a robust 30.6 per cent year-on-year growth in Q2 FY2022.

It added that growth for the sample set was primarily led by new launches, low base, strong demand and rupee depreciation.

As for the US market, the revenue growth for the sample set remained muted at 1.9 per cent during the second quarter owing to high single-digit to low teens price erosion and past inventory liquidation given the Covid-19-related uncertainties, it added.

The outlook for the pharma sector remains stable led by healthy revenue growth and margins, ICRA said.

It added that it expects the sample set's capital structure and coverage indicators to remain comfortable despite higher capex and R&D (research and development) expenses given the robust cash levels.

Also Read:Indian Pharma industry to grow at 11 percent, surpass USD 60 billion in 2 years: Care Ratings